Immuneering Corporation (IMRX)
1.48
-0.17 (-10.30%)
At close: Mar 03, 2025, 3:59 PM
1.50
1.43%
After-hours: Mar 03, 2025, 04:56 PM EST
Company Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates.
Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.
The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs.
Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Immuneering Corporation

Country | United States |
IPO Date | Jul 30, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 66 |
CEO | Dr. Benjamin J. Zeskind M.B.A., Ph.D. |
Contact Details
Address: 245 Main Street Cambridge, Massachusetts United States | |
Website | https://immuneering.com |
Stock Details
Ticker Symbol | IMRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001790340 |
CUSIP Number | 45254E107 |
ISIN Number | US45254E1073 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, Chief Executive Officer & Director |
Leah R. Neufeld | Chief People Officer |
Michael D. Bookman J.D. | Chief Legal Officer & Secretary |
Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
Dr. Peter King Ph.D. | Head of Discovery & Vice President |
Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology & Vice President |
Harold E. Brakewood | Chief Business Officer |
Mallory Morales CPA | Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer |
Paula George CPA | Director of Accounting & Operations and Assistant Corporate Controller |
Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 07, 2025 | 4 | Filing |
Feb 07, 2025 | 4 | Filing |
Feb 07, 2025 | 4 | Filing |
Feb 07, 2025 | 4 | Filing |
Feb 07, 2025 | 4 | Filing |
Feb 07, 2025 | 4 | Filing |
Jan 17, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 13, 2025 | 8-K | Current Report |
Jan 07, 2025 | 8-K | Current Report |
Jan 02, 2025 | 4 | Filing |